Biocon Biologics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Biocon Biologics (US): 2 reconciled FDA prescription therapies, $0 2024 CMS Part D & Medicaid spend, and $3,184 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
California HCAI SB 17 FilingsSpecialty launch notice ($3,184 intro WAC)